Tauopathies Treatment Market: Introduction
- As per the NCBI (National Center for Biotechnology Information), tauopathies are described as neurodegenerative disorders caused by abnormal deposition of tau protein in the brain. Major tauopathies disorders include Pick’s disease, corticobasal degeneration, argyrophilic grain disease, and progressive supranuclear palsy. Emerging tauopathies disorders are primary age-related tauopathy including neurofibrillary tangle dementia, chronic traumatic encephalopathy (CTE), and aging-related tau astrogliopathy. Moreover, globular glial tauopathies in which tau is further characterized by astrocytic inclusions and globular tau-reactive oligodendroglial are considered as emerging tauopathies disorders. The globular glial tauopathies is further classified into three sub-types based on distribution of inclusions. Clinical symptoms of tauopathies include frontotemporal dementia, pure akinesia, Richardson syndrome, Parkinsonism, corticobasal syndrome, and motor neuron symptoms of cerebellar ataxia. In some neurodegenerative disorders, specific image of tau deposition is captured due to neuroimaging features. Tauopathies also occur due to novel concept of cell to cell distribution process.
- Proper diagnosis is required to diagnose these neurodegenerative disorders in patients, for which cost-effective screenings are recommended. Thus, examination of amygdala, hippocampus, and basal ganglia is widely preferred by the neurosurgeons. Ongoing clinical trial and research would help understand cause and treatment of the tauopathies condition in the near future.
Key Drivers and Restraints of Global Tauopathies Treatment Market
- Ongoing research & development to develop drugs for tauopathies treatment is likely to be a driving factor for the market at global level. Increase in investments and rise in health care spending by the government are a few attributable growth factors. As per research, currently, no approved treatments are available for tauopathies protein found in neurodegenerative diseases, although as per research, the first approved drug would be a boon for the tauopathies treatment.
- Regulatory approval process and supportive reimbursment policies are likely to setup therapeutic approach for tauopathies treatment. The clinical trials on developing farnesyltransferase inhibitor and disease-modifying drugs are expected to drive the global market in the next few years. However, the research is a time consuming process and currently no approved drugs are present in the market. These factors are expected to restrain the tauopathies treatment market.
North America to Lead Global Tauopathies Treatment Market
- In terms of region, the global tauopathies treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
- North America is projected to dominate the tauopathies market during the forecast period, owing to established research & development, investments in the late stage clinical development of drugs for tauopathies, supportive health care expenditure, government initiatives, and diagnosis of symptoms of tauopathies. Rise in incidence of neurodegenerative diseases such as Alzheimer’s and Parkinson’s; and presence of pharmaceutical and research companies in the region are likely to boost the tauopathies treatment market. Moreover, surge in health care expenditure, advanced health care facilities, and expanding contract research organizations in the market are anticipated to boost the growth of the tauopathies market in the region.
- Europe is estimated to hold the second largest share of the global market in the next few years, followed by Asia Pacific. Diagnosis of tauopathy condition in 20 neurodegenerative diseases and investments by pharmaceutical companies and governments for research & development of treatment are expected to drive the market in Europe. Furthermore, rise in awareness about tauopathies treatment and initiatives by the government are likely to fuel the growth of the tauopathies treatment market in Asia Pacific region.
Key Manufacturers Operating in Global Tauopathies Treatment Market
The global tauopathies treatment market consists of only a few players including pharmaceutical and small clinical stage companies involved in drugs development for treating tauopathies. Some of these players are:
- Avanir Pharmaceuticals, Inc.
- Otsuka Pharmaceutical Co., Ltd
- AB Science
- TauRx
- Sellas
- Catalent Inc.
Global Tauopathies Treatment Market: Research Scope
Global Tauopathies Treatment Market, by Disease
- Alzheimer’s Disease
- Frontotemporal Degeneration
- Progressive Supranuclear Palsy (PSP)
- Corticobasal Degeneration (CBD)
- Pick’s Disease
- Other Neurodegenerative Diseases
Global Tauopathies Treatment Market, by End-user
- Hospitals
- Specialized clinics
- Others
Global Tauopathies Treatment Market, by Region
- North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
